Boehringer Ingelheim Secures US FDA’s EUA for NexGard and NexGard COMBO to Treat NWS

Why It Matters

The EUA gives veterinarians a fast‑acting, FDA‑backed option against a lethal parasite, potentially reducing animal mortality and expanding Boehringer's market share in veterinary parasitic control.

Key Takeaways

• FDA grants EUA for NexGard against New World screwworm
• NexGard chewables approved for dogs 8 weeks+, 4 lbs+
• NexGard COMBO topical approved for cats 8 weeks+, 1.8 lb+
• EUA expands Boehringer's veterinary parasitic portfolio
• NWS poses severe risk to livestock and pets

Pulse Analysis

New World screwworm (NWS) remains one of the most aggressive parasitic threats to both livestock and companion animals across the Americas. The larvae burrow deep into tissue, causing rapid tissue necrosis, secondary infections, and often fatal outcomes if untreated. Historically, control relied on broad‑spectrum insecticides and preventive measures, but the lack of a specific, FDA‑approved therapeutic for pets left a critical gap. The recent Emergency Use Authorization signals a regulatory shift, acknowledging the urgent need for targeted interventions in the veterinary space.

NexGard, known for its afoxolaner active ingredient, has long been a staple oral flea and tick treatment for dogs. By extending its formulation to address NWS, Boehringer leverages a proven safety profile—approved for puppies as young as eight weeks and weighing four pounds—to deliver rapid systemic action against the parasite. The companion product, NexGard COMBO, offers a topical solution for cats and kittens, also cleared for animals eight weeks old and a minimum weight of 1.8 pounds. Both products provide convenient dosing schedules, aligning with routine veterinary visits and enhancing compliance among pet owners.

From a market perspective, the EUA positions Boehringer Ingelheim at the forefront of a niche yet high‑impact segment of veterinary pharmaceuticals. The approval not only diversifies the company's product portfolio but also sets a precedent for future fast‑track authorizations of parasite‑specific therapies. As NWS outbreaks continue to affect agricultural regions, the availability of effective treatments for pets could drive broader adoption of integrated pest‑management strategies, ultimately benefiting animal health, farmer productivity, and the overall veterinary drug market.